CMS assigns J-code for Eisai's Halaven Injection to treat breast cancer

NewsGuard 100/100 Score

Eisai Inc. announced today that the Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Halaven® (eribulin mesylate) Injection. Halaven was approved in November 2010 to treat metastatic breast cancer - breast cancer that has spread - in patients who have received at least two other types of anticancer medicines. Previous therapy should have included an anthracycline and a taxane for either early or advanced breast cancer. The new J-code, J9179, became effective on January 1, 2012.

"We are very pleased to have received the J-Code," said Dave Martin, Vice President, Managed Markets, Value and Access, Eisai Inc. "It will help facilitate reimbursement for providers who have patients who may be candidates for Halaven treatment, thus ensuring access to those patients who need it."

Source: Eisai

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Plant-based diets reduce cancer and heart disease risks, study shows